The central target of $13.50 is the arithmetic mean of 13 verified analyst price targets, ranging from a low of $4.63 to a high of $30. With shares near $9.98 , reaching $13.50 would require a move of roughly 35% , a substantial but not extreme advance.
Sunrun (RUN) shares climbed roughly 31% over the last 30 days, rising from about $7.61 to approximately $9.98 on the strength of a blowout third-quarter earnings report. The company posted Q3 revenue of $1.1 billion (up 52% year over year), well above consensus estimates of about $757.5 million, and adjusted EPS of $0.56 versus a $0.16 estimate.
SUNation Energy (SUNE) is expected to report third-quarter fiscal 2026 results in mid-November, following its calendar-year reporting schedule. The company's most recent quarter showed continued pressure: Q2 2026 revenue fell about 37.5% year over year to $8.16 million, with a net loss of $3.34 million.
SNSC eased -2.74% during regular market hours, drifting to about $0.71 from a prior close of $0.73. No verified news or fundamental catalyst found; the decline likely reflects continued speculative drift in this thinly traded, recently listed micro-cap, which averages roughly a 6.6% daily swing.
Third-quarter 2025 revenue reached $393.5 million , up 70% year over year and well above analyst estimates. The company swung to a net income of $33.5 million , a sharp reversal from a $141.4 million net loss a year earlier.
Third-quarter 2026 revenue reached $32.8 million , up 25.4% sequentially and 26.1% year over year, landing above the midpoint of management's target range. Non-GAAP gross profit swung to $2.8 million (8.4% of revenue), compared with a non-GAAP gross loss of $1.3 million in the prior quarter.
Third quarter 2026 revenue came in at $24.0 million, down 21.5% year over year and slightly below the consensus estimate of $25.33 million. GAAP (Generally Accepted Accounting Principles) net income reached $0.4 million, a sharp swing from a $2.2 million net loss in the prior-year quarter, with earnings per share of $0.01 versus a consensus loss of $0.02.
Revenue surged 43.8% year over year to $195.3 million, easily topping the consensus estimate of roughly $162 million. Adjusted diluted earnings per share (EPS) came in at $0.14, above the $0.12 analysts had expected.
The central price target of $1.00 is not an analyst-derived figure; SNSC has no active sell-side coverage, so the target reflects a psychological recovery level and technical milestone rather than a Wall Street consensus. The stock closed near $0.74, meaning reaching $1.00 would require a gain of roughly 35% — a substantial move for a thinly traded micro-cap.
SNSC shares have declined roughly 31% over the past 30 days, falling from about $1.19 to approximately $0.82. The drop extends a steep post-IPO selloff that began shortly after the company's August 2026 debut at $5.00 per share.
First Solar reported third-quarter 2026 net sales of $1.23 billion , down 23% year over year, as module volumes sold to third parties declined. Net income rose 25% to $571 million , or $5.30 per diluted share , beating profit expectations despite the top-line decline.
Nextracker reported record revenue of $1.1 billion for its second quarter of fiscal year 2027, beating consensus estimates by roughly $40 million. Non-GAAP earnings per share (EPS, or profit divided by shares outstanding) came in at $1.31 , topping analyst expectations by about $0.21.
Enphase Energy (ENPH) shares have declined roughly 18% over the last 30 days, driven chiefly by a third-quarter earnings miss and fourth-quarter guidance that came in well below Wall Street expectations. Third-quarter revenue of $293.3 million fell about 29% year over year and missed the consensus of roughly $305 million, while adjusted EPS of $0.41 came in below the approximately $0.50 analysts expected.
SEDG is trading down -9.11% to $29.23 during regular market hours, versus a prior close of $32.16. Primary catalyst: peer Enphase Energy's disappointing Q3 results and weak Q4 revenue guidance sparked a broad selloff across solar names, dragging SEDG lower.
Enphase Energy (ENPH) is down -15.49% to $25.15, extending losses that began in after-hours trading following Tuesday's Q3 results. The drop was driven by a Q3 miss—revenue of $293.3M and adjusted EPS of $0.41 both below estimates—plus Q4 revenue guidance of $225M–$255M, far below the ~$300M consensus.
ARRY (Array Technologies) is a solar tracking equipment manufacturer showing improving profitability, a record order book, and positive momentum, while INO (Inovio Pharmaceuticals) is a pre-revenue biotech whose value hinges on a single pending regulatory decision. The two companies operate in unrelated sectors—renewable-energy hardware versus DNA medicines—making this comparison a study in contrasting risk profiles rather than direct competition.
ARRY is a solar tracking systems manufacturer with a record orderbook but sharply negative recent price momentum, while SEER is an early-stage proteomics (large-scale protein analysis) company trading near its 52-week low. Both stocks are unprofitable on a net-income basis, but their profiles diverge sharply: ARRY generates roughly $1.2 billion in trailing revenue versus SEER's approximate $14 million.
ARRY is a profitable-momentum industrial story tied to solar energy demand, while AVXL is a pre-revenue biotech whose value hinges on regulatory outcomes. ARRY has expanded margins and built a record orderbook in recent quarters, whereas AVXL has faced regulatory setbacks and governance-related headlines.
Array Technologies (ARRY) is a solar-tracking hardware manufacturer with growing revenue visibility but recent revenue declines and a volatile, lower-priced stock. Ocugen (OCGN) is a clinical-stage biotech with no approved products, relying on late-stage gene-therapy milestones for its valuation case.
Allogene Therapeutics (ALLO) is a clinical-stage biotech advancing "off-the-shelf" allogeneic CAR T cell therapies, while Array Technologies (ARRY) is a commercial manufacturer of solar tracking systems for utility-scale projects. ALLO's recent performance has been driven by positive trial data for its lead candidate, cema-cel, while ARRY has posted record order-book growth despite pressure on its share price in recent weeks.